Purpose of Review The neurogenic bladder is a medical term that describes a variety of bladder and sphincter dysfunctions. There are two major dangerous functional problems in a child with neurogenic bladder: high intravesical pressure in the storage phase and high pressure during urination. Two basic goals for urologic treatment in those children are protection of urinary tract from complications and improvement of continence in older children. This review focuses on the current role of botulinum toxin treatment in children with neurogenic bladder. Recent Findings At the beginning, treatment in this group of children is conservative. Oral anticholinergic therapy is aimed at decreasing bladder pressures during the storage phase. Clean intermittent catheterization enables bladder emptying if voiding is insufficient. Nevertheless, in a number of children such an approach fails, in some patients, troublesome side effects occur. In cases when standard therapy provides no improvement or if complications develop on the proper conservative treatment, surgical procedures are suggested. Operations are aimed at the surgical enlargement of bladder capacity. There are some reports on the efficacy of cystoscopic detrusor botulinum toxin injections in the treatment of neurogenic bladder in children. Summary Cystoscopic administration of botulinum toxin represents an alternative method of treatment to surgery for children with neurogenic bladder and could be considered an alternative to oral anticholinergic therapy.
Introduction-Function of the Lower Urinary Tract
The lower urinary tract, as one operating unit, consists of two anatomical parts, namely bladder and sphincters. The normal function of the lower urinary tract is to store urine for a reliable period of time and then evacuate it in a coordinated, controlled fashion. Proper age-related bladder capacity with continence in the storage phase and complete bladder emptying in the voiding phase are the most important factors. This coordinated activity of the lower urinary tract is regulated by many parts of the central and peripheral nervous systems. Neurogenic bladder (NB) is a medical term applied to a variety of bladder dysfunctions due to known neurological pathology [1] [2] [3] .
In children younger than the age of 3 to 5 years, urination occurs involuntarily. At this period of life, voiding is controlled by the autonomic part of the central nervous system. In older children, it is regulated voluntarily. The evaluation of the bladder function in older children should begin with voiding diary (VD). VD or frequency/volume chart contains data on the hours and volumes of voided/catheterized urine as well as episodes of urine incontinence. The most important data from VD are the daytime number of micturitions, the average voided or catheterized volume of urine, and number of incontinence episodes per day. The data of maximal and functional bladder capacity from VD should be supported by urodynamic tests (UD) that are used to investigate both volume and specific for the volume pressures are recorded [4] .
The most frequently used formula for the calculation of age-related bladder capacity for children is expected bladder capacity (EBC): volume (ml) = 30 × [age (in years) + 1] . Bladder capacity increases with the age from 30 mL in neonates to 350 mL in 12-year-old children [5, 6] .
Groups of Patients

Normal Bladder Function
The child is urinating regularly in volumes of urine adequate to EBC, without any complaints.
Children Voiding Abnormally
The child is urinating periodically but the volumes are not correct. There are three subgroups: a) Increased voiding frequency with decreased volumes of urine. Vol < 65% EBC and > 8 voids per day (OAB = overactive bladder syndrome with frequency and urgency symptoms). b) Decreased voiding frequency with large volumes of urine.
Vol > 150% EBC, and < 3 voids per day (LBS = lazy bladder syndrome or voiding postponements). c) Irregular voiding characterized by considerable differences in the voided volume in the consecutive urinations. In this group of children, significant residual urine is seen frequently (more than 10-20% of voided volume).
Each of those conditions may be accompanied with additional symptoms, such as urgency, hesitancy, straining, or intermittency. In each group, urine incontinence or urinary tract infections may occur.
Children Who Have Lost Control Over Their Bladder and Do Not Urinate at all
The lack of control over urination is due to lack of sensation of bladder fullness and lack of urethral sensation or in whom that sensation is considerably decreased. This is characteristic of severe cases of the NB [3, 6] .
Neurogenic Bladder
Congenital malformations, acquired diseases or injuries of any part of a nervous system, can influence the function of bladder and sphincters leading to problems with urination or even to complete loss of ability to urinate and urinary incontinence. The most common cause of NB in children is dysraphism malformations. Other causes of NB are cerebral palsy, sacral agenesis, tethered spinal cord, or malformations associated with imperforate anus, cloacal malformations, and spinal cord injuries. A child with NB should first undergo physical examination. Further tests are urinalysis and urine culture, biochemical tests, abdominal ultrasound, and UD investigations. Further examinations like cystography, renal scans, intravenous pyelography, and computed tomography are optional [1] [2] [3] 6] .
Urodynamic Investigation
UD evaluations describe bladder function and dysfunction of the bladder and sphincters. Analyzing data from UD investigations, Madersbacher [7] described four groups of patients with NB: a) Detrusor overactivity with sphincter overactivity b) Detrusor inactivity with sphincter overactivity c) Detrusor overactivity with sphincter inactivity d) Detrusor inactivity with sphincter inactivity Based on this simple classification of NB, the therapeutic strategy is provided for each child. The most important factors from UD investigations predicting risk of complications are as follows: a) Increased above 40-cm H2O detrusor leak point pressure (DLPP)
DLPP is the lowest value of detrusor pressure at which leakage is observed in the absence of abdominal strain or detrusor contraction. b) Decreased bladder compliance, less than 20-mL/cm H2O Bladder compliance is the relationship between change in bladder volume (ΔV) and change in detrusor pressure. (ΔPdet): C = ΔV/ΔPdet (mL/cmH2O).
DSD is a detrusor contraction simultaneous with contraction of the urethra and/or periurethral striated muscle activity. d) Elevated storage pressure with decreased bladder capacity Both are caused by detrusor overactivity (DO). Decrease in storage pressure could be gained by correcting DO and increasing bladder compliance [3, 6, [8] [9] [10] [11] [12] [13] [14] [15] .
DO is a urodynamic observation characterized by involuntary detrusor contraction during the filling phase which may be spontaneous or provoked. The diagnosis of DO is based on the observations from UD investigations. If those contractions are caused by a neurogenic condition, we call them neurogenic DO. The neurogenic DO is most commonly seen in children with SD and spinal cord injury but can also be seen in patients with cerebral palsy. In the majority of cases in the literature, urinary incontinence among patients with underlying neurological conditions was found to be associated with DO [6, 8, 9, 12] .
Treatments and Procedures
Conservative Treatment
That treatment of a child with NB begins with the conservative methods. The two most important forms of conservative treatment of a child with NB are clean intermittent catheterization (CIC) and correction of elevated bladder pressure.
Optimization of Bladder Emptying
The aim of this treatment is the protection of urinary tract from urinary tract infections due to residual urine and protection of upper urinary tract from the development of complications due to high voiding pressure.
Clean Intermittent Catheterization Jack Lapides introduced CIC in 1972 as a method of bladder emptying in patients with NB [16] . This method is simple and effective. It can be performed beginning in the newborn period. CIC empties the bladder completely without any residual urine and by this, it is decreasing the risk of urinary tract infections and keeps the child safe of vesico-ureteric reflux due to high voiding pressure. In older children, it is a valuable tool to keep the child dry [1, 3, 8, 12, 13] .
α-Blockers DSD leads to ineffective voiding with significant residual urine, and it is one of the fundamental functional problems in a child with NB. The sympathetic part of the autonomic nervous system is primarily responsible for urine continence. In the sphincter and bladder neck muscles, a prevalence of α 1 -andregenic receptors is found. Their activation increases the sphincter mechanism tension, and their inactivation enables voiding. Since the 1970s, α 1 -blockers have been used to reduce sphincter tension and to eliminate functional infravesical obstruction. Those drugs act through reversible blocking of α 1 -adrenergic receptors located in the muscles of the bladder neck and urethral sphincters [17, 18] .
Several preparations are available in the group of α 1 -selective blockers, but none of those drugs have formal approval for usage in children, so treatment with any α 1 -blocker is off label. There are only few reports on the use of α 1 -blockers in children with NB and infravesical obstruction. Data from those studies are conflicting, showing variable degree of efficacy, so there is no evidence for this kind of treatment [19] [20] [21] [22] [23] .
Decreasing Elevated Storage Pressure
The aim of decreasing storage pressure is the protection of urinary tract from the development of complications and improvement of continence in older children.
Antimuscarinics Antimuscarinic or anticholinergic drugs represent the golden standard of pharmacologic treatment of increased intravesical pressure. DO, involuntary contractions of the detrusor muscle are mediated by acetylcholine-induced stimulation of muscarinic receptors. Oxybutynin was introduced in the 1970s, and anticholinergic drugs are associated with a 40% increased likelihood of improvement and significantly decreased number of leakage and voiding episodes compared with placebo. Antimuscarinics have antispasmodic and local anesthetic properties that augment its effect on DO. Muscarinic M1 receptors are found also in the brain, salivary glands, and intestine sympathetic ganglia, which are responsible for most of the side effects noted during antimuscarinic therapy. Dry mouth, constipation, and elevated body temperature are the most common side effects on anticholinergic therapy. Gastroesophageal reflux, blurry vision, urinary retention, and cognitive adverse events can also occur. These symptoms are generally less frequent and less bothersome in children than in adults. Seven different antimuscarinic drugs are currently available on the market: oxybutynin, solifenacin, tolterodine, propiverine, trospium chloride, darifenacin, and fesoterodine, but not all of them have gained registration for treatment in children with NB [24] [25] [26] [27] [28] . β 3 -Adrenoceptor Agonist Mirabegron is a β 3 -adrenoceptor agonist developed for the treatment of DO. The β 3 -adrenoceptor plays an important role in the relaxation of the detrusor muscle. Mirabegron acting β 3 -adrenoceptor relaxes the detrusor muscle during the storage phase with increasing bladder capacity. Mirabegron appears to be a safe and effective alternative for children with side effects on antimuscarinic therapy or with DO refractory to antimuscarinics, but, so far, its usage in children is off label [29, 30] .
Surgical Treatment
The gold standard in the treatment of a child with neurogenic bladder for DO is oral therapy with anticholinergic drugs [31, 32••, 33] . Nevertheless, in a number of children, such an approach fails to increase bladder volume and decrease detrusor pressure, low bladder capacity, and urinary incontinence persists. In some patients, troublesome side effects occur. In cases when standard therapy gives no improvement or if complications develop on the proper conservative treatment, surgical procedures are suggested. Operations are aimed at the surgical enlargement of bladder capacity.
At present, bladder augmentation represents the most effective way of surgical improvement of bladder's function, leading to an increase in capacity and a decrease in intravesical pressure [31] [32] [33] [34] [35] . However, augmentation cystoplasty is a major reconstructive surgery with a significant complication rate [36] . One of the main indications for the use of BTX in children with NB is to delay or avoid the need for augmentation cystoplasty [37, 38••, 39] . Especially in younger children, the operative vesicostomy provides an effective way to evacuate urine to decrease intravesical pressures [40, 41] . Cystoscopic administration of BTX represents an alternative method of treatment to surgery for children with NB [42] .
Botulinum Toxin
Botulinum toxin (BTX) was first isolated from Clostridium botulinum bacteria by van Ermengem. Originally, seven serotypes of BTX were described, but botulinum toxin A is used most frequently in the urologic field. Two forms of BTX-A, o n a b o t u l i n u m t o x i n A ( B o t o x ® , A l l e r g a n ) a n d abobotulinumtoxinA (Dysport®, Ibsen), have been evaluated for the treatment of NDO. The outcomes of both are comparable [37, 43] .
Both the American Urologic Association (AUA) and the European Association of Urology (EAU) guidelines suggest that intravesical injection of BTX should be offered to patients with urgency urinary incontinence refractory to antimuscarinic therapy. The US Food and Drug Administration (FDA) approved BTX in 2011 for neurogenic and idiopathic detrusor overactivity. Recently, there are ongoing some trials for formal registration of Botox administration in children with NDO and IDO [44, 45] .
The BTX molecule is composed of a 100 kDa heavy and a 50 kDa light chain polypeptides joined by a disulfide bond. The initial proposed mechanism of BTX action was that by attachment of the heavy chain to the receptor SV2 on axon terminals, the toxin could enter the neuron by endocytosis. The light chain cleaves synaptosomal-associated protein SNAP-25. As a result, the fusion of neurosecretory vesicles and the release of acetylcholine from pre-synaptic nerve terminals are blocked. The toxin penetrates the cell membrane and temporarily blocks the pre-synaptic release of acetylcholine from the parasympathetic efferent innervations. With the inhibition of acetylcholine release, the effect on suburothelial afferent and detrusor parasympathetic nerve endings is abolished, which was similar to the action of anticholinergic drugs [46] [47] [48] .
The suggested mechanism is multidirectional and involves acting not only on the fusion protein SNAP-25, synaptic protein VAMP, but also Substance P, muscular receptors M2 and M3, capsaicin receptor TRPV1, purinergic receptor P2X2, P2X3, urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF-Beta-1), tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), and other factors. The action of BTX is reversible [49] [50] [51] [52] .
In urology, BTX has been used as a cystoscopic procedure (CS) mainly to inject detrusor muscles in order to decrease intravesical pressure in the storage phase, but it has also been applied to sphincters to abolish DSD effect in the voiding phase. Most of the reports pertained to the treatment of adult patients, but some of them reported good results also in children [32••, 33-35, 37-39, 53, 54] . A systematic review of BTX treatment in children was performed by Hascoet in 2016. This study included 12 studies with 293 patients younger than 18 years of age. In this review, there was no randomized trial comparing BTX-A versus placebo and most studies had no control group. It was concluded that most studies demonstrated an improvement in both clinical symptoms and UD parameters. Complete resolution of incontinence occurred in 32-100% of patients. Two studies suggested that BTX has lower efficacy in patients with low bladder compliance. Intradetrusor injections of BTX could be effective in children with NB but this possibility is not supported by a high level of evidence [32••] . There are no reports of randomized, doubleblind, placebo controlled clinical trials on children with NB treated with BTX.
In 2005, Schurch randomized 59 patients with NB to receive a single dose of 200 U or 300 U BTX or placebo and concluded that intradetrusor injection of BTX was associated with a clinically significant improvement in urinary incontinence caused by DO [55] . In another randomized, doubleblind, placebo-controlled trial reported by Herschorn, patients experienced a reduction in their urinary incontinence by 50% with improvement in urodynamic parameters after BTX injection [56] . In four randomized double-blind, placebocontrolled trials on a total of 807 patients, BTX effectively improved clinical outcomes and urodynamic findings in patients with neurogenic DO [57] .
Cystoscopic Procedure
According to the literature, while many children undergo CS under general anesthesia, it has been reported that CS could be performed without any anesthesia, as the majority of children with NB and MMC have no sensation of the lower urinary tract. During CS, a rigid or flexible cystoscope with an operative channel is used. The diameter of the instrument should be adjusted to the age of a patient and the size of the urethra. The bladder is filled with the solution. A rigid needle is introduced through the operative channel of a cystoscope. The dose of BTX is calculated for every patient according to the age and the body mass, and diluted in 10-20 ml 0.9% NaCl. The dose of the toxin is administered in divided portions into the bladder dome. In the majority of studies, 20-30 consecutive sites of bladder dome were injected each with a small portion of the solution [32••, 33-35, 37, 38••, 39, 53-57, 58•] . Some authors postulated only ten injection sites are necessary while others concluded that up to 50 consecutive injections are needed [37, 59] .
The injection is performed into the detrusor muscle while some authors suggested to inject it superficially: suburothelial/ submucosal [60•, 61] . Some urologists postulated not to inject the preparation into regions of ureteric orifices sparing the trigone [59, 62, 63] . Others advised to inject the BTX preparation also into the bladder trigone [64, 65•, 66] . Following the procedure, urine is evacuated from the bladder by catheterization.
In a study from 2018 intravesical electromotive method of BTX (Dysport), administration in patients with NDO was investigated. The results of this study have shown that this method is a feasible, safe, reproducible, cost-effective, long-lasting, and pain-free method on an outpatient basis without anesthesia or cystoscopy procedure. This delivery system resulted in considerable improvement in urinary incontinence and urodynamic study parameters in patients with refractory NDO [67] .
Effects of BTX Detrusor Injection
The expected effect of BTX detrusor injection should be increased in bladder capacity and decrease in intravesical pressure. The outcomes of BTX injections are assessed both in VD and UD investigations. UD examinations are essential for the assessment of the functioning of the lower urinary tract and are recommended as a routine part of the follow-up in children after BTX injection [68••] .
In the literature, some parameters from cystometric evaluation were measured and compared. First, most authors noted an increase in maximal cystometric capacity (MCC) with a decrease of maximum detrusor pressure (MDP) [37] . In a study by Neel, MCC increased significantly from 96 to 163 ml, and the MDP decreased significantly from 76 to 50 cm H2O [69] . Schulte-Baukloh reported MCC change from 163.1 to 219.9 ml, MDP changed from 59.6 to 34.9 cm H2O [35] . Efficacy of BTX injections in the detrusor and an increase in MCC with a decrease of MDP has been noted by other authors in 32 to 100% of patients [32••, 33-35, 37-39, 53-57, 58•] . In some papers, detrusor reflex volume (DRV), volume at which the first detrusor contraction occurred, was measured [37, 39] . According to SchulteBaukloh, in the follow-up cystometry, mean reflex volume changed from 97.1 ml before injection to 178.6 ml after 4 weeks [35] .
It is still disputable if intradetrusor injections of BTX will affect the tension of sphincters reflected by a change in DLPP and bladder walls compliance. In some studies, positive changes in DLPP were observed after BTX injection in detrusor muscle. In a study from 2012, leak point pressure decreased from 46.5 to 24.2 cm H2O [58•] . The 66% clinical success rate described by Hascoet was significantly associated with a decrease in maximum urethral closure pressure (34 cm H2O vs 54.4 cm H2O) [2] . In a randomized trial of 60 patients with NB: in one group, 10 IU/kg of BTX was injected into the detrusor muscle; in the second group: 8 IU/kg into detrusor and 2 IU/kg in external urethral sphincter. It was found that additional BTX injections in sphincter have extra benefits such as decreasing postvoiding residual volume and more symptom diminution compared with intradetrusal injections alone [34] .
BTX injection has shown effectiveness in the treatment of detrusor sphincter dyssynergia when injected into sphincters either transurethral or transperineally. After treatment, external urethral sphincter pressure, voiding pressure, and post-void residual volume demonstrate a decrease. The effect is reported to last between 2 and 12 months. [70] In a study of Mokhless, endoscopic injection of a dose of 100 IU of Botox into the hypertrophied bladder neck does not improve the outcome of boys with voiding dysfunction after valve ablation [71] .
Bladder compliance improvement was observed by some authors [32••, 38••, 39, 58•, 72], others did not agree with this observation [33, 34, 73] . Botulinum toxin A injection in the NB was found to be ineffective if the detrusor was fibrotic, of low compliance, and had lost contractility [74] . Even poor bladder compliance was described as predictor of poor response after BTX-A injection [75] .
Continence
The increase in bladder capacity should be reflected in the improvement in continence status. This was measured in different scales by some authors. In a study of SchulteBaukloh, there was 33% reduction in the score at week 2-4 after the cystoscopic procedure [35] . According to Khan, 75% of patients were continent between CIC [33] . Similar improvements (73%) were noted by Kajbafzadeh, and the total improvement in urine incontinence was 88% [46] . Figueroa reported the 76.9% improvement in continence was followed by 70.6% overall patient/parental reported satisfaction rate [77] . In a recent, multicenter study, clinical improvement was noted in 66% of patients [32••] . In a group of children described by Khan, overall 54% of children had improved continence after the initial BTX injection, whereas 45% had achieved complete continence between catheterizations [3] . In a study from 2007, from a clinical point of view, 9 of the 16 incontinent patients (56.2%) showed complete continence after treatment while 4 (25%) reported mild to moderate improvement and 3 (18.8%) showed no improvement [79] . In other studies, 50 to 100% of patients were dry at 3-6 months after the BTX injection. [34, 37, 59, 72, 78] 
Dosage
Only onabotulinum, Botox (Allergan) has registration for treatment DO, but there are some studies on abobotulinum, Dysport (Ibsen) treatment of DO in urology. Those two preparations are not equivalent both in the duration of action and effective dosage. Taken together, the findings retrieved from the literature suggest a conversion ratio of 1:3 or 1:4 for Botox and Dysport. In NBO in adults, a dosage of BTX has been reported at 500 to 1500 units of abobotulinum or 100 to 300 units of onabotulinum. In children, respectively 10-30 U/kg body weight abobotulinum or 2.5-12 U/kg body weight of onabotulinum were used [37, 43-45, 54, 57, 79] . The most commonly used dose of onabotulinum toxin in these patients is 10-12 U/kg with a maximal dose of 300 U [5, 7, 24, [27] [28] [29] . In a study of Altaweel, the bladder was injected with 5 U/kg body weight with a maximum dosage of 300 IU for patient. Safari used 8 or 10 U/kg, Riccabona and Kajbafzadeh 10 U/ kg, Do Ngoc Thanh 6-11 U/kg, and Schulte-Baukloh 12 U/kg to a maximum of 360 U per patient [35, 39, 59, 62, 63, 76, 78] .
Estimating the optimal dosage of BTX preparations both in children and adults is still under investigation. Some papers showed, both for Botox or Dysport, no clear dose-related effect with the observation indicating that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo [37] . One dose ranging study on rats with Dysport and Botox under standardized conditions showed similar inhibiting effects on NDO [43] .
Persistence of Effect
The activity of BTX in the urinary bladder was described to persist for 6-9 months and with reports as long as 12 months. Afterwards, the procedure can be repeated. In a study of Herschorn, improved urodynamic parameters for treatment vs placebo persisted to weeks 24 to 36 [56] . In a group of 28 children described by Zeino, the efficacy of BTX injection lasted a mean of 12 months and the urodynamic response was unchanged even after several injections [58•] . Also in the observations of Horst, 12 months after treatment, patients still had an effect [73] . According to Riccabona, mean durability of the effect of the drug was 10.5 months after the first as well as after the second intravesical injection [59] . In a study of Kask, median duration of the response after BTX injection was 15 months (range 3-42 months) [34] .
Only one controlled study reported the effects of different dosages of BTX for treatment patients with DO at 36 weeks [80] .
Repeated Injections
In many observations, repeated intradetrusor BTX injections were found to be equally effective as the first application. In some studies, the procedure was repeated more than ten times with the same effect as the first injection [37, 38••, 39, 47, 57, 58•, 65•, 72] . In some studies, Botox remained effective after up to 11 injections [81] .
Influence on Upper Urinary Tract
Improvement in bladder function can lead to resolution of vesicoureteral reflux. In a study by Kajbafzadeh et al. of 15 patients with varying degrees of vesicoureteral reflux before the procedure, 11 (73%) had a decrease in the reflux grade [76] . Simultaneous BTX injection in detrusor and sphincters showed better outcomes in relation to the resolution of vesicoureteral reflux than intra detrusor BTX injection alone [63] . Further improvement in the treatment of children with complications of NB is the total endoscopic management which is a combination of intradetrusor BTX injection along with endoscopic treatment of vesicoureteral reflux. Fifteen out of 16 (93.75%) refluxing ureters were completely resolved by this kind of treatment [82•] . BTX treatment may confer longterm bladder and upper tract protection in the neurogenic patient group, treating new-onset hydronephrosis secondary to the neurogenic bladder [81] . Furthermore, BTX treatment was found to be a cost-effective therapy for OB and should be further explored as a first line option in the treatment paradigm [83••] .
Side Effects
According to the data from many studies, serious adverse events (SAE) related to the procedure of BTX injection have been reported [31, 32••, 37, 38••, 57, 72, 84] . The most common adverse event after BTX injection was urinary tract infection. Elevated post-void residual were seen in patients voiding spontaneously. In a study of Greer, three children (2.8%) developed urinary retention after intravesical BTX injection [81] . In another study, post procedure urinary retention requiring catheterization was only 1.6% [85] . In reports from other studies, none of the patients had side effects related to the procedure or the material used. But caution must be taken when BTX-A is used in patients under age 18 years of age. BTX is specified as pregnancy category C, where there are no adequate and well-controlled studies in children and it should only be used if the potential benefits justify the potential risk to the fetus [33, 56, 69, 86, 87] .
Follow-up Recommendations for Children Following BTX Injection
Currently, there are no available guidelines for follow up after intravesical BTX injection. Due to the risk of developing complications also in children under proper conservative treatment, patients with NB need periodic urology check-ups and repeated diagnostic tests. Further regular follow-up visits at the urology office are mandatory. The evaluation of the bladder function in children starts with completing VD. Urinalysis should be performed monthly and urine culture only in the case of symptomatic urinary tract infections. Abdominal US and UD testing to be performed every 6-12 months according to risk factors. Video-UD or cystography and renal scans should be performed immediately in case of confirmed change in urinary tract function, continence status, or deterioration in urinary tract confirmed in US [3, 7, 8, 56, 58•] .
Conclusions
Endoscopic administration of the BTX should be considered an alternative method of treatment of children with NB in the following cases: lack of efficacy on oral conservative treatment, side effects of anticholinergic drugs, and lack of parental consent to surgical treatment (vesicostomy or surgical bladder augmentation). This kind of treatment could be also considered an alternative to oral anticholinergic therapy.
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